An open label study to assess the efficacy, safety and tolerability of Cozaar plus (losartan potassium 50mg/hydrochlorothiazide 12.5mg) possibly titrated up to Cozaar plus-F (losartan potassium 100mg/hydrochlorothiazide 25mg) in patients with essential hypertension

Trial Profile

An open label study to assess the efficacy, safety and tolerability of Cozaar plus (losartan potassium 50mg/hydrochlorothiazide 12.5mg) possibly titrated up to Cozaar plus-F (losartan potassium 100mg/hydrochlorothiazide 25mg) in patients with essential hypertension

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Apr 2017

At a glance

  • Drugs Losartan/hydrochlorothiazide (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 18 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top